{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:51:00Z","timestamp":1761630660330},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/mot.0b013e3283651b0d","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T16:13:16Z","timestamp":1377879196000},"page":"549-554","source":"Crossref","is-referenced-by-count":8,"title":["Cancer\u2013infection interface in children after transplantation"],"prefix":"10.1097","volume":"18","author":[{"given":"Mikiya","family":"Fujieda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoshi","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20211004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12253-010-9329-8","article-title":"Lymphoproliferative disorders after solid organ transplantation - classification, incidence, risk factors, early detection and treatment options.","volume":"17","author":"Vegso","year":"2011","journal-title":"Pathol Oncol Res"},{"key":"R2-9-20211004","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","article-title":"Epstein-Barr virus-related posttransplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.","volume":"11","author":"Nourse","year":"2011","journal-title":"Am J Transplant"},{"key":"R3-9-20211004","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2165\/11316180-000000000-00000","article-title":"Adverse effects of immunosuppression in pediatric solid organ transplantation.","volume":"12","author":"Schonder","year":"2010","journal-title":"Pediatr Drugs"},{"key":"R4-9-20211004","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2165\/11635690-000000000-00000","article-title":"Managing posttransplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.","volume":"72","author":"Murukesan","year":"2012","journal-title":"Drugs"},{"key":"R5-9-20211004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/TP.0b013e31823ae7db","article-title":"Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.","volume":"93","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"key":"R6-9-20211004","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MOT.0b013e32835741cd","article-title":"New immunosuppressants in pediatric solid organ transplantation.","volume":"17","author":"Marks","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"R7-9-20211004","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"R8-9-20211004","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transplant"},{"key":"R9-9-20211004","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5414\/CNP70393","article-title":"Monitoring of Epstein-Barr virus load and killer T cells in pediatric renal transplant recipients.","volume":"70","author":"Sato","year":"2008","journal-title":"Clin Nephrol"},{"key":"R10-9-20211004","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/j.1600-6143.2012.04197.x","article-title":"A 16-year multiinstitutional study of role of age and EBV status on PTLD incidence among pediatric heart transplant recipients.","volume":"12","author":"Chinnock","year":"2012","journal-title":"Am J Transplant"},{"key":"R11-9-20211004","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","article-title":"Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of posttransplant lymphoproliferative disorder in kidney transplant recipients.","volume":"27","author":"Sampaio","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R12-9-20211004","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1600-6143.2011.03893.x","article-title":"Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States.","volume":"12","author":"Dharnidharka","year":"2012","journal-title":"Am J Transplant"},{"key":"R13-9-20211004","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00467-011-1812-2","article-title":"Monitoring and managing viral infections in pediatric renal transplant recipients.","volume":"27","author":"Comoli","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R14-9-20211004","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1442-200X.2008.02579.x","article-title":"Monitoring of Epstein-Barr virus load and antibody in pediatric renal transplant patients.","volume":"50","author":"Sato","year":"2008","journal-title":"Pediatr Int"},{"key":"R15-9-20211004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5414\/CN106572","article-title":"Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients.","volume":"76","author":"Ishihara","year":"2011","journal-title":"Clin Nephrol"},{"key":"R16-9-20211004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12185-011-0951-3","article-title":"Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS posttransplant lymphoproliferative disorder.","volume":"94","author":"Shimizu","year":"2011","journal-title":"Int J Hematol"},{"key":"R17-9-20211004","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1111\/j.1399-0012.2011.01535.x","article-title":"Effect of early EBV andor CMV viremia on graft function and acute cellular rejection in pediatric liver transplantation.","volume":"26","author":"Indolfi","year":"2012","journal-title":"Clin Transplant"},{"key":"R18-9-20211004","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1399-0012.2012.01608.x","article-title":"Quantitative Epstein-Barr virus shedding and its correlation with the risk of posttransplant lymphoproliferative disorder.","volume":"26","author":"Holman","year":"2012","journal-title":"Clin Transplant"},{"key":"R19-9-20211004","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jcv.2011.11.010","article-title":"Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after hematopoietic stem cell transplantation.","volume":"53","author":"Ruf","year":"2012","journal-title":"J Clin Virol"},{"key":"R20-9-20211004","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of posttransplant lymphoproliferative disease.","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"R21-9-20211004","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/jmv.22242","article-title":"Epstein-Barr virus gene expression and latent membrane protein 1 gene polymorphism in pediatric liver transplant recipients.","volume":"83","author":"Kasztelewicz","year":"2011","journal-title":"J Med Viol"},{"key":"R22-9-20211004","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/TP.0b013e3182247bf2","article-title":"Epstein-Barr virus gene expression, human leukocyte antigen alleles and chronic high viral loads in pediatric renal transplant patients.","volume":"92","author":"Moran","year":"2011","journal-title":"Transplantation"},{"key":"R23-9-20211004","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1399-3046.2010.01465.x","article-title":"Asymptomatic high Epstein-Barr viral load carriage in pediatric renal transplant recipients.","volume":"15","author":"Tanaka","year":"2011","journal-title":"Pediatr Transplant"},{"key":"R24-9-20211004","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1399-3046.2012.01750.x","article-title":"Effective control of Epstein-Barr virus infection following pediatric liver transplantation by monitoring of viral DNA load and lymphocyte surface markers.","volume":"16","author":"Imadome","year":"2012","journal-title":"Pediatr Transplant"},{"key":"R25-9-20211004","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/eji.201141832","article-title":"Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD.","volume":"42","author":"Wiesmayr","year":"2012","journal-title":"Eur J Immunol"},{"key":"R26-9-20211004","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1600-6143.2011.03954.x","article-title":"Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder.","volume":"12","author":"Engels","year":"2012","journal-title":"Am J Transplant"},{"key":"R27-9-20211004","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/j.1600-6143.2011.03968.x","article-title":"CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD.","volume":"12","author":"Schiffer","year":"2012","journal-title":"Am J Transplant"},{"key":"R28-9-20211004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2010.08160.x","article-title":"Management of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS guidelines.","volume":"149","author":"Parker","year":"2010","journal-title":"Br J Haematol"},{"key":"R29-9-20211004","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/j.1600-6143.2012.04206.x","article-title":"Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Childrens Oncology Group Report.","volume":"12","author":"Gross","year":"2012","journal-title":"Am J Transplant"},{"key":"R30-9-20211004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2141.2011.08855.x","article-title":"Preemptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.","volume":"155","author":"Worth","year":"2011","journal-title":"Br J Haematol"},{"key":"R31-9-20211004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1399-3046.2012.01656.x","article-title":"Emerging therapeutic strategies for Epstein-Barr virus posttransplant lymphoproliferative disorder.","volume":"16","author":"Hatton","year":"2012","journal-title":"Pediatr Transplant"},{"key":"R32-9-20211004","doi-asserted-by":"crossref","first-page":"37368","DOI":"10.1074\/jbc.M111.255125","article-title":"Syk activation of phosphatidylinositol 3-kinaseAkt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus (EBV) B cell lymphomas.","volume":"286","author":"Hatton","year":"2011","journal-title":"J Biol Chem"},{"key":"R33-9-20211004","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","article-title":"(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation.","volume":"25","author":"Hocker","year":"2012","journal-title":"Transpl Int"},{"key":"R34-9-20211004","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1399-3046.2009.01258.x","article-title":"The changing face of posttransplant lymphoproliferative disease in the era of molecular EBV monitoring.","volume":"14","author":"Kerkar","year":"2010","journal-title":"Pediatr Transplant"},{"key":"R35-9-20211004","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1399-3046.2012.01731.x","article-title":"Posttransplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.","volume":"16","author":"Cleper","year":"2012","journal-title":"Pediatr Transplant"}],"container-title":["Current Opinion in Organ Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00075200-201310000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T09:22:36Z","timestamp":1633512156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00075200-201310000-00009"}},"subtitle":["posttransplant lymphoproliferative disorder and Epstein-Barr virus infection"],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mot.0b013e3283651b0d","relation":{},"ISSN":["1087-2418"],"issn-type":[{"value":"1087-2418","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}